Premium
α1 D / A ‐adrenoceptor antagonist naftopidil for the male lower urinary tract symptoms associated with benign prostatic hyperplasia: Efficacy of dose increase therapy
Author(s) -
Yamaguchi Satoshi,
Osanai Hiroaki,
Numata Atsushi,
Watanabe Masaki,
Kakizaki Hidehiro
Publication year - 2013
Publication title -
international journal of urology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.172
H-Index - 67
eISSN - 1442-2042
pISSN - 0919-8172
DOI - 10.1111/j.1442-2042.2012.03188.x
Subject(s) - medicine , international prostate symptom score , urology , lower urinary tract symptoms , prostate , hyperplasia , quality of life (healthcare) , group b , urinary system , nursing , cancer
Objectives To examine the efficacy of dose increase therapy in patients with lower urinary tract symptoms associated with benign prostatic hyperplasia who responded poorly to 50 mg/day of naftopidil. Methods A total of 95 patients received 50 mg/day of naftopidil for 8 weeks. After this treatment period, they were divided into two groups: the poor responders were defined as those who either had an International Prostate Symptom Score‐Quality of Life ≥4 or with an International Prostate Symptom Score‐Quality of Life of 3 whose International Prostate Symptom Score‐Quality of Life improved <2 points (group A ). All other patients were defined as responders to naftopidil 50 mg/day (group B ). The dose of naftopidil was increased to 75 mg/day in group A , and maintained at 50 mg/day in group B . The treatment was continued for a further 8 weeks. Results The prostate volume at the baseline was significantly larger in group A than group B . The improvement of International Prostate Symptom Score total score, International Prostate Symptom Score‐Quality of Life, and voided volume after 8 weeks was significantly better in group B than in group A . However, there was no significant difference in the changes of all parameters between the two groups after 16 weeks. Conclusions A dose increase to 75 mg/day is an effective treatment strategy in patients with lower urinary tract symptoms associated with benign prostatic hyperplasia who responded poorly to an initial dose of 50 mg/day of naftopidil. Furthermore, a starting dose of 75 mg/day should be considered in patients with a large prostate volume, as this is a predictive factor for dose increase.